RMD Open最新文献

{"title":"Correction: COVID-19 outcomes in patients with rheumatoid arthritis with biologic or targeted synthetic DMARDs.","authors":"","doi":"10.1136/rmdopen-2023-003038corr1","DOIUrl":"10.1136/rmdopen-2023-003038corr1","url":null,"abstract":"","PeriodicalId":21396,"journal":{"name":"RMD Open","volume":"11 3","pages":""},"PeriodicalIF":5.1,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12225288/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144542087","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic value of high-frequency ultrasound assessment of the lacrimal glands for primary Sjögren's disease.","authors":"L Terslev, Nanna Surlemont Schmidt, Mads Ammitzbøll-Danielsen, Viktoria Fana","doi":"10.1136/rmdopen-2025-005884","DOIUrl":"10.1136/rmdopen-2025-005884","url":null,"abstract":"<p><strong>Objectives: </strong>The aim of the study was to evaluate the ultrasound findings in lacrimal glands in a cohort of patients with suspected primary Sjögren's disease (pSjD) and to assess the relationship with the diagnosis and the association with functional tests and autoantibodies.</p><p><strong>Methods: </strong>Patients with suspected pSjD, evaluated by salivary gland ultrasound (SGUS) and lacrimal gland (LGUS) as part of the diagnostic set-up were included. All had unstimulated sialometry, Schirmer's test and laboratory test done (including autoantibodies). Ultrasound examination was performed with a GE Logiq E10 (a linear 4-20 MHz transducer for SGUS and a 6-24 MHz hockey stick transducer for LGUS). The OMERACT consensus-based greyscale scoring system (0-3) for salivary glands was applied for all glands. A score of ≥2 was considered pathological.</p><p><strong>Results: </strong>30 patients were included, one was subsequently excluded due to missing data, 13 were diagnosed with pSjD according to the American College of Rheumatology/EULAR classification criteria. The sensitivity and specificity for LGUS for pSJD diagnosis were 61.5 and 87.5, respectively. The PPV and NPV values were 80.0 and 73.3, respectively-better than SGUS for the current cohort. There was no statistically significant association between LGUS and Schirmer's test positivity (p value: 0.86), but there was a significant association between LGUS and SSA (OR: 17.4, p=0.005) as well as SSB (OR: 23.0, p=0.003).</p><p><strong>Conclusion: </strong>LGUS has moderate sensitivity and high specificity for the diagnosis of pSjD. The OMERACT scoring system appears relevant for scoring pathology in the lacrimal glands using grade ≥2 as cut-off and may be a valuable supplementary tool for diagnostic evaluation in pSjD.</p>","PeriodicalId":21396,"journal":{"name":"RMD Open","volume":"11 3","pages":""},"PeriodicalIF":5.1,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12215119/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144542088","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"New horizons in systemic sclerosis treatment: advances and emerging therapies in 2025.","authors":"Cristiana Sieiro Santos, Francesco Del Galdo","doi":"10.1136/rmdopen-2025-005776","DOIUrl":"10.1136/rmdopen-2025-005776","url":null,"abstract":"<p><p>Systemic sclerosis (SSc) is a rare, multisystem autoimmune disease characterised by vasculopathy, immune dysregulation, and progressive fibrosis, leading to significant morbidity and mortality. While recent EULAR recommendations have updated the standard of care for SSc, the field is rapidly evolving with novel therapeutic strategies and precision medicine approaches.Traditional immunosuppressive therapies-including mycophenolate mofetil, cyclophosphamide and rituximab-remain essential for controlling skin and lung involvement while autologous haematopoietic stem cell transplantation offers a proven disease-modifying option for selected high-risk patients. Tocilizumab and nintedanib have established roles in lung preservation in SSc-associated interstitial lung disease (SSc-ILD). In pulmonary arterial hypertension (PAH), early combination therapy with endothelin receptor antagonists and phosphodiesterase-5 inhibitors, complemented by newer agents such as selexipag and riociguat, has improved survival and quality of life. Advances in gastrointestinal, renal and musculoskeletal management continue to evolve, with promising roles for intravenous immunoglobulin and novel prokinetics.Crucially, emerging therapies-including CD19-targeted CAR-T cells, bispecific antibodies and agents targeting interferon pathways, BAFF, melanocortin, FcRn and PDE4B-reflect a shift towards personalised and biomarker-driven approaches. These innovations offer the potential to alter disease trajectory and support early, targeted intervention in SSc.This review provides an up-to-date synthesis of both current organ-based treatment strategies in major organ domains-skin, ILD, PAH, scleroderma renal crisis, raynaud's phenomenon and digital ulcers, gastrointestinal and musculoskeletal involvement-and emerging therapies in SSc, with an emphasis on disease-modifying approaches and future directions in personalised care.</p>","PeriodicalId":21396,"journal":{"name":"RMD Open","volume":"11 3","pages":""},"PeriodicalIF":5.1,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12215137/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144542089","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Thrombin generation test as a useful tool for improving disease severity stratification in antiphospholipid syndrome.","authors":"Cecile Yelnik, Anne Bauters, Julien Labreuche, Maximilien Desvages, David Launay, Eric Hachulla, Sylvain Dubucquoi, Steve Lancel, Marie Frimat, Marc Lambert","doi":"10.1136/rmdopen-2025-005489","DOIUrl":"10.1136/rmdopen-2025-005489","url":null,"abstract":"<p><strong>Background: </strong>Patients with antiphospholipid syndrome (APS) display a wide range of clinical manifestations with similar immunological profile with the presence of lupus anticoagulant in around 70% of them. Although antiphospholipid antibodies (aPL) profile influences the risk of thrombosis in APS, APS risk stratification remains to be improved.</p><p><strong>Objectives: </strong>Our study aimed to evaluate thrombin generation test (TGT) interest to improve disease severity stratification in APS patients.</p><p><strong>Patients/methods: </strong>In this monocentric, transversal study, we included unselected primary thrombotic APS patients, fulfilling APS classification criteria and treated by vitamin K antagonist (VKA). 28 non-APS patients under VKA followed in our hospital were included as controls. TGT was performed on plasma samples with the calibrated automated thrombogram in our core laboratory.</p><p><strong>Results: </strong>Between January 2020 and March 2023, 114 thrombotic APS patients (without systemic lupus erythematosus) were included (female 71 (62.3%), mean age 50±14 years old, median duration since the last APS event of 51 months (IQR 23-129 months)). APS patients had prolonged lag time (LT) and time to peak (TTP) compared with anticoagulated controls. History of relapse, catastrophic APS (CAPS), all aPL positivities and elevated Bb fragments were strongly associated with a prolonged LT and TTP.</p><p><strong>Conclusions: </strong>Our findings suggest that APS patients under VKA had significantly prolonged TGT times compared with anticoagulated controls, with the greatest prolongations in patients with history of relapse or CAPS. Thus, TGT might be a useful tool to improve APS disease severity stratification without temporary cessation of VKA.</p>","PeriodicalId":21396,"journal":{"name":"RMD Open","volume":"11 3","pages":""},"PeriodicalIF":5.1,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12215132/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144542090","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Collecting patient-reported outcomes via the COTIDIANA smartphone app: a prospective validity study.","authors":"Nasim Nakhost Lotfi, Francisco Nunes, Pedro Matias, Tanja A Stamm, Ricardo Graca, Nadja Kartschmit, Daniel Aletaha, Elsa Frãzao-Mateus, Helga Radner, Paul Studenic","doi":"10.1136/rmdopen-2025-005730","DOIUrl":"10.1136/rmdopen-2025-005730","url":null,"abstract":"<p><strong>Background: </strong>Self-management of rheumatic and musculoskeletal diseases often involves regular assessments of disease-related outcomes. In recent years, smartphone apps are used to collect electronic patient-reported outcomes (ePROMs), supporting the self-management process and improvement of health-related quality of life. We aimed to assess the reliability and comparability of frequent remote monitoring by using ePROMs via a smartphone.</p><p><strong>Methods: </strong>Patients (≥18 years) with Sjögren's disease (SjD), osteoarthritis (OA) and psoriatic arthritis (PsA) were recruited from our outpatient clinic and asked to complete seven short daily as well as weekly questions (visual analogue scale) on global disease activity (PGA), pain, anxiety and depression, fatigue and sleep) for 14 days. To assess reliability, intraclass correlation (ICC) for 1-6-day test-retest intervals, as well as the smallest detectable difference (SDDs), were calculated. Convergent validity was evaluated via correlation of daily and weekly ePROMs.</p><p><strong>Results: </strong>48 patients (76.12% female: 18 SjD, 20 PsA, 10 OA) were included for analyses. At the 1-day test-retest interval, ICCs ranged between 0.84 and 0.89 and SDDs from 1.04 to 2.10, for all domains. The 6-day interval presented wider reliability with ICCs from 0.23 to 0.73 and SDDs from 1.89 to 2.88. While all measures demonstrated high test-retest reliability during the 1-, 2- and 3-day intervals (ICC: 0.83-0.98), an increase in SDDs and a decrease in ICCs were observed as intervals extended. Daily measured ePROMs highly correlated with its corresponding weekly ePROM (pain=0.97, anxiety and depression=0.94, fatigue=0.90, sleep=0.95, PGA=0.94).</p><p><strong>Conclusion: </strong>Reliability was particularly stable at shorter intervals with more variation over time. Convergent validity was high between daily and weekly assessment. Short ePROMs collected via smartphones may offer flexibility to vary assessment times while maintaining consistent reliability.</p>","PeriodicalId":21396,"journal":{"name":"RMD Open","volume":"11 2","pages":""},"PeriodicalIF":5.1,"publicationDate":"2025-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12207126/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144512449","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Computed tomography-derived quantitative imaging biomarkers enable the prediction of disease manifestations and survival in patients with systemic sclerosis.","authors":"Malte Maria Sieren, Hanna Grasshoff, Gabriela Riemekasten, Lennart Berkel, Felix Nensa, Rene Hosch, Jörg Barkhausen, Roman Kloeckner, Franz Wegner","doi":"10.1136/rmdopen-2024-005090","DOIUrl":"10.1136/rmdopen-2024-005090","url":null,"abstract":"<p><strong>Introduction: </strong>Systemic sclerosis (SSc) is a complex inflammatory vasculopathy with diverse symptoms and variable disease progression. Despite its known impact on body composition (BC), clinical decision-making has yet to incorporate these biomarkers. This study aims to extract quantitative BC imaging biomarkers from CT scans to assess disease severity, define BC phenotypes, track changes over time and predict survival.</p><p><strong>Materials and methods: </strong>CT exams were extracted from a prospectively maintained cohort of 452 SSc patients. 128 patients with at least one CT exam were included. An artificial intelligence-based 3D body composition analysis (BCA) algorithm assessed muscle volume, different adipose tissue compartments, and bone mineral density. These parameters were analysed with regard to various clinical, laboratory, functional parameters and survival. Phenotypes were identified performing K-means cluster analysis. Longitudinal evaluation of BCA changes employed regression analyses.</p><p><strong>Results: </strong>A regression model using BCA parameters outperformed models based on Body Mass Index and clinical parameters in predicting survival (area under the curve (AUC)=0.75). Longitudinal development of the cardiac marker enabled prediction of survival with an AUC=0.82. Patients with altered BCA parameters had increased ORs for various complications, including interstitial lung disease (p<0.05). Two distinct BCA phenotypes were identified, showing significant differences in gastrointestinal disease manifestations (p<0.01).</p><p><strong>Conclusion: </strong>This study highlights several parameters with the potential to reshape clinical pathways for SSc patients. Quantitative BCA biomarkers offer a means to predict survival and individual disease manifestations, in part outperforming established parameters. These insights open new avenues for research into the mechanisms driving body composition changes in SSc and for developing enhanced disease management tools, ultimately leading to more personalised and effective patient care.</p>","PeriodicalId":21396,"journal":{"name":"RMD Open","volume":"11 2","pages":""},"PeriodicalIF":5.1,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12198789/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144497976","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Determinants of social participation in patients living with systemic lupus erythematosus: the Psy-LUP multicentre study.","authors":"Cécile Manet, Marie-Anastasie Aim, Viviane Queyrel, Julien Faraut, Nathalie Costedoat-Chalumeau, Eric Daugas, Eric Hachulla, Jean-Robert Harle, Antoine Huart, Aurélie Hummel, Gilles Kaplanski, Karin Mazodier, Julien Mancini, Francoise Sarrot-Reynauld, Nicolas Schleinitz, Laure Swiader, Nathalie Tieulie, Philippe Manet, Lionel Dany, Laurent Chiche, Noemie Jourde-Chiche","doi":"10.1136/rmdopen-2025-005661","DOIUrl":"10.1136/rmdopen-2025-005661","url":null,"abstract":"<p><strong>Objective: </strong>Systemic lupus erythematosus (SLE) can negatively impact patients' social participation. The aim of this study was to identify the determinants of social participation in patients with SLE.</p><p><strong>Methods: </strong>A cross-sectional evaluation was carried out in 100 adult outpatients with SLE enrolled in the multicentre psychosocial lupus (Psy-LUP) study. Participants completed the following standardised questionnaires: Participation Scale (social participation); Zimbardo Time Perspective Inventory; Sarason's Social Support Questionnaire; Couples Satisfaction Index; Brief Illness Perceptions; Short Form-36 and Lupus-QoL. Stepwise multivariate regression analysis identified determinants of social participation.</p><p><strong>Results: </strong>92 women and eight men were included. Mean age was 44 years, mean SLE duration was 14 years, 52% of patients had a history of lupus nephritis and 38% were currently receiving immunosuppressants and/or biologics. 73% were in a couple and 64% were employed. Social participation was reduced in 29% of patients (compared with 46% in rheumatoid arthritis or multiple sclerosis), who reported different illness perceptions than those with preserved social participation. In multivariate linear regression, female sex (p=0.006), smoking (p=0.04), osteoporotic fractures (p=0.03), anti-cardiolipin antibodies (p=0.01) and 'Past Negative' time perspective (p=0.002) were associated with reduced social participation, while haematological involvement (p=0.005) and 'Present Hedonistic' time perspective (p=0.02) were protective. Reduced social participation was also associated with illness representations and with lower health-related quality of life (HR-QoL) scores.</p><p><strong>Conclusions: </strong>Social participation is frequently altered in patients with SLE and correlates with illness representations, time perspective and HR-QoL. Psychological support and therapeutic education may help improve patients' time perspective.</p><p><strong>Trial registration number: </strong>NCT03913754.</p>","PeriodicalId":21396,"journal":{"name":"RMD Open","volume":"11 2","pages":""},"PeriodicalIF":5.1,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12198841/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144497978","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cycle versus swap strategy after TNFi discontinuation in psoriatic arthritis and axial spondyloarthritis: a quasi-experimental study.","authors":"Ilse van Es, Johanna E Vriezekolk, Nathan den Broeder, Lisan de Beijer, Alfons A den Broeder, Noortje van Herwaarden, Elien Mahler, Emmerik F A Leijten","doi":"10.1136/rmdopen-2025-005566","DOIUrl":"10.1136/rmdopen-2025-005566","url":null,"abstract":"<p><strong>Objectives: </strong>To compare a bDMARD mode of action cycle vs swap treatment strategy in patients with psoriatic arthritis (PsA) or axial spondyloarthritis (axSpA) after first tumour necrosis factor inhibitor (TNFi) discontinuation.</p><p><strong>Methods: </strong>In December 2019, our local treatment protocol for PsA and axSpA changed from a cycle strategy (first TNFi to second TNFi) to a swap strategy (first TNFi to IL-17i). We performed a retrospective comparison of the 3-year drug retention rate using multivariable Cox regression (ref: cycle group) and disease activity (DAS28-CRP for PsA, BASDAI for axSpA) in patients with a clinical diagnosis of PsA and axSpA. For subgroup analyses, Cox regression models were stratified by sex, reason of first TNFi discontinuation, and (non-)radiographic status in axSpA.</p><p><strong>Results: </strong>In PsA patients (n=406), there was no overall significant difference in drug retention between strategies (HR: 1.17 (95% CI: 0.87 to 1.58), p=0.29), but male PsA patients had a significant higher risk for treatment discontinuation following a swap strategy. In axSpA patients (n=335), the swap strategy was overall associated with a higher risk of treatment discontinuation (HR: 1.46 (95% CI: 1.03 to 2.07), p=0.04). Patients who discontinued their first TNFi due to inefficacy and patients diagnosed with radiographic axSpA were at significant higher risk for treatment discontinuation following a swap strategy. No significant differences in disease activity were found for treatment strategies in PsA or axSpA.</p><p><strong>Conclusion: </strong>In PsA, the cycle and swap treatment strategy performed similarly, while in axSpA, the cycle strategy was associated with a significant higher drug retention rate.</p>","PeriodicalId":21396,"journal":{"name":"RMD Open","volume":"11 2","pages":""},"PeriodicalIF":5.1,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12198808/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144497977","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical and genetic determinants of worse sexual experience in male patients with radiographic axial spondyloarthritis: a multimodal study.","authors":"Lidong Hu, Dai Gao, Xiaojian Ji, Yiwen Wang, Xingkang Liu, Jianglin Zhang, Jian Zhu, Feng Huang","doi":"10.1136/rmdopen-2025-005594","DOIUrl":"10.1136/rmdopen-2025-005594","url":null,"abstract":"<p><strong>Objective: </strong>The expression and experience of sexuality is a key part of an individual's self-identity, yet it is often overlooked in clinical settings. This study aims to evaluate the impact of radiographic axial spondyloarthritis (r-axSpA) on sexual experience in male patients, identify contributing factors and explore the potential causal relationship between r-axSpA and erectile dysfunction (ED).</p><p><strong>Methods: </strong>We assessed the sexual experience of 113 male patients with r-axSpA and 73 healthy people using the Sexual Experience Questionnaire in the cross-sectional study. Linear regression analysis was used to explore the contributions of clinical factors to worse sexual experience. A two-sample Mendelian randomisation (MR) design was conducted to examine the potential causal association of r-axSpA with the risk of ED.</p><p><strong>Results: </strong>There was a significant difference in the total sexual experience score between patients with r-axSpA and healthy controls (41.81±8.71 vs 50.23±8.82, p<0.001). Patients with r-axSpA had a worse score in all dimensions of sexual experience, including erectile function, individual satisfaction and couple satisfaction, compared with healthy individuals. In the regression model adjusted for age, disease duration and body mass index, disease activity (Bath Ankylosing Spondylitis Disease Activity Index), physical function (Bath Ankylosing Spondylitis Functional Index), mobility (Bath Ankylosing Spondylitis Metrology Index, chest expansion and finger-floor distance), health index (Assessment of SpondyloArthritis international Society Health Index), sleep quality (Pittsburgh Sleep Quality Index) and psychological status (Hospital Anxiety and Depression Scale (HADS), HADS-Anxiety and HADS-Depression) were significant determinants of sexual experience. The two-sample MR analysis demonstrated no causal effect of r-axSpA on the risk of ED (OR: 0.973; 95% CI: 0.824 to 1.149; p=0.749) based on the inverse variance weighted method. Sensitivity analyses supported the result, with no evidence of directional pleiotropy.</p><p><strong>Conclusions: </strong>Worse sexual experience was associated with increased disease activity, reduced mobility, lower health index, poor sleep quality and psychological status. Genetic-level evidence indicated no direct causal relationship between r-axSpA and ED. Therefore, actively assessing disease-related suffering and developing new management strategies are essential for improving sexual experience in patients with r-axSpA.</p>","PeriodicalId":21396,"journal":{"name":"RMD Open","volume":"11 2","pages":""},"PeriodicalIF":5.1,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12198791/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144497975","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"High-frequency ultrasound can detect inflammatory changes of the finger pulleys anatomical entheses in early psoriatic arthritis.","authors":"Luis Coronel, Chiara Rizzo, Maribel Miguel-Pérez, Maria Antonietta D'Agostino, Ingrid Möller","doi":"10.1136/rmdopen-2025-005783","DOIUrl":"10.1136/rmdopen-2025-005783","url":null,"abstract":"","PeriodicalId":21396,"journal":{"name":"RMD Open","volume":"11 2","pages":""},"PeriodicalIF":5.1,"publicationDate":"2025-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12198779/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144485762","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}